Roche launches Cobas 5800 molecular Dx system in CE markets

January 2022—Roche launched its Cobas 5800 system in countries accepting the CE mark. The real-time PCR molecular testing solution is built to offer a fully automated workflow that encompasses sample supply, transfer and preparation, amplification and detection, result calculation, and delivery to the laboratory information system. The single module enables a walkaway time of up to eight hours.

“Diagnostics continue to revolutionize how providers care for patients, and it is essential, now more than ever, that the health care community has access to reliable and accurate testing solutions,” Thomas Schinecker, CEO of Roche Diagnostics, said in a press statement. ”We are pleased that we can now offer a compact, fully automated molecular system such as the Cobas 5800 system. This new system helps to address the high demands on labs through greater efficiency, optimized workflows, and cost savings, enabling them to deliver quality patient care.”

The Cobas 5800 will have the same menu as the Cobas 6800/8800 systems, including the Cobas SARS-CoV-2 test. It offers an expanded onboard capacity that allows labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift.

Roche anticipates receiving FDA approval during the fourth quarter of 2022. The system is not yet available in the United States.

Roche, 317-521-2000